Efficacy and safety of sublingual immunotherapy using a combination of <i>Dermatophagoides pteronyssinus</i> and <i>Blomia tropicalis</i> extracts in patients with allergic rhinitis: A randomized, double-blind, placebo-controlled trial.

ABSTRACT:

Background

Allergen immunotherapy is the only treatment that may modify the natural course of allergic diseases. Sublingual immunotherapy (SLIT) is a promising treatment, especially for children. Few studies currently exist related to optimal dosing for Blomia tropicalis.

Methods

This was a double-blind, randomized, placebo-controlled trial of SLIT to treat house dust mite-induced Allergic Rhinitis (AR). A total of 65 patients, ages 12-16 years, were treated for 12 months and randomized into SLIT versus placebo. The SLIT group received a combination of Dermatophagoides pteronyssinus and Blomia tropicalis allergens. Sensitization was confirmed by skin prick test or serum specific IgE. Total Nasal Symptom Score (TNSS), Rhinoconjunctivitis Quality of Life Q

SUBMITTER: Macedo PRC 

PROVIDER: S-EPMC11815642 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature